The venture capital group's cooperative sub-fund successfully listed the company Youzhiyou Biotechnology on the main board of the Hong Kong Stock Exchange.

On September 25, 2023, the Nanjing Innovation Investment Group's cooperative sub-fund - Nanjing Huada Gongying No. 1 Venture Capital Enterprise (Limited Partnership) (referred to as "Huada Gongying No. 1 Fund") successfully listed its invested company - Wuhan Youzhiyou Biological Pharmaceutical Co., Ltd. (hereinafter referred to as "Youzhiyou Biological", stock code: 2496.HK) on the main board of the Hong Kong Stock Exchange.

The Huada Gongying No. 1 Fund was established on September 7, 2017, with a fund size of 370 million yuan, and the Nanjing Industrial Development Fund Co., Ltd. contributed 70 million yuan. The fund manager, Huada Gongying (Shenzhen) Equity Investment Fund Management Co., Ltd., is a venture capital institution with the industrial background of Huada Group, possessing the dual advantages of CVC and VC institutions in industrial resources and flexible decision-making mechanisms, covering all stages of investment in high-quality project enterprises in the region. As of now, the Huada Gongying No. 1 Fund has invested in 15 projects, of which 3 projects have been listed, 2 projects are preparing to apply for IPO, and 1 project has completely exited. The fund invested in Youzhiyou Biological in December 2020, empowering the company in business docking, corporate strategic development, and other aspects to assist its growth.

Youzhiyou Biological is a biotechnology company dedicated to developing bispecific antibody (dual antibody) therapies for the treatment of cancer-related complications, cancer, and age-related ophthalmic diseases. Since its establishment in 2010, Youzhiyou Biological has adhered to independent innovation, focusing on and deeply cultivating the bispecific antibody field, developing four innovative platforms, including its self-developed YBODY® platform, Check-BODY platform, Nano-YBODYTM platform, and the UVAX® platform developed in collaboration with the Wuhan Institute of Virology; it has designed and developed seven candidate drug product pipelines that have entered clinical stages; 80% of its R&D personnel are engaged in research, and it holds 78 patents (of which 33 are authorized, and 45 are under examination).

Source: Fund Department Shao Yifu

Reviewed by: Xue Yao

Published by: You Yi